You have 9 free searches left this month | for more free features.

Nivolumab

Showing 1 - 25 of 1,700

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Melanoma Trial in Rotterdam (Nivolumab)

Recruiting
  • Melanoma
  • Nivolumab
  • Rotterdam, Pending, Netherlands
    Erasmus MC
Oct 30, 2023

Recurrent Glioblastoma Trial in Brussels (Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV,

Not yet recruiting
  • Recurrent Glioblastoma
  • Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV
  • +2 more
  • Brussels, Belgium
    UZ Brussel
Oct 23, 2023

Melanoma Trial (ABP 206, FDA-licensed Nivolumab, EU-authorized Nivolumab)

Not yet recruiting
  • Melanoma
  • ABP 206
  • +2 more
  • (no location specified)
Jun 8, 2023

Tumors, Carcinoma, Squamous, Antineoplastic Agents Trial (Nivolumab Injection [Opdivo])

Not yet recruiting
  • Neoplasms
  • +2 more
  • Nivolumab Injection [Opdivo]
  • (no location specified)
Jul 19, 2023

Melanoma Trial (ABP 206, Nivolumab)

Not yet recruiting
  • Melanoma
  • ABP 206
  • Nivolumab
  • (no location specified)
Sep 20, 2023

Advanced Soft-tissue Sarcoma Trial (Lurbinectedin)

Not yet recruiting
  • Advanced Soft-tissue Sarcoma
  • (no location specified)
May 26, 2023

Acute Anterior ST Segment Elevation Myocardial Infarction Trial (Nivolumab, Placebo)

Not yet recruiting
  • Acute Anterior ST Segment Elevation Myocardial Infarction
  • Nivolumab
  • Placebo
  • (no location specified)
Jun 6, 2023

Melanoma Trial in Worldwide (relatlimab+nivolumab, relatlimab+nivolumab+rHuPH20, nivolumab)

Not yet recruiting
  • Melanoma
  • Anchorage, Alaska
  • +28 more
Oct 20, 2023

Merkel Cell Carcinoma Trial in Wollstonecraft (Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination)

Not yet recruiting
  • Merkel Cell Carcinoma
  • Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination
  • Wollstonecraft, New South Wales, Australia
    Melanoma Institute Australia
Nov 21, 2023

Renal Cell Carcinoma Trial in Houston (Tivozanib, Nivolumab)

Not yet recruiting
  • Renal Cell Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Sep 19, 2023

Melanoma Stage IV, Melanoma Stage III, Immunetherapy Trial (nivolumab)

Not yet recruiting
  • Melanoma Stage IV
  • +3 more
  • nivolumab
  • (no location specified)
Dec 14, 2022

Melanoma (Skin) Trial in Houston (BMS-986213 (Relatlimab-Nivolumab FDC), Nivolumab, Relatlimab)

Not yet recruiting
  • Melanoma (Skin)
  • BMS-986213 (Relatlimab-Nivolumab FDC)
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 1, 2023

Cutaneous Squamous Cell Carcinoma Trial in Amsterdam (Nivolumab, Ipilimumab)

Recruiting
  • Cutaneous Squamous Cell Carcinoma
  • Amsterdam, Noord Holland, Netherlands
    NKI-AVL
Oct 24, 2022

Advanced Glioblastoma, Metastatic Melanoma in the CNS, MGMT-Unmethylated Glioblastoma Trial in Ramat Gan (Crizanlizumab-Tmca 10

Not yet recruiting
  • Advanced Glioblastoma
  • +2 more
  • Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]
  • Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]
  • Ramat Gan, Israel
    Sheba medical center
Jun 11, 2023

Squamous Cell Carcinoma of Head and Neck Trial (Combination 5-azacytidine and nivolumab, 5-azacytidine, Nivolumab)

Not yet recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • Combination 5-azacytidine and nivolumab
  • +2 more
  • (no location specified)
Dec 7, 2022

RCC, Renal Cell Carcinoma Trial in Dallas (Cabozantinib 80 MG, Cabozantinib 40Mg Tab, Nivolumab)

Not yet recruiting
  • RCC
  • Renal Cell Carcinoma
  • Cabozantinib 80 MG
  • +2 more
  • Dallas, Texas
    UT Southwestern Medical Center
Jul 3, 2023

Immune Suppression, Gastric Cancer Trial in Hangzhou (nivolumab combined with SOX)

Recruiting
  • Immune Suppression
  • Gastric Cancer
  • nivolumab combined with SOX
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Feb 11, 2023

Melanoma, Metastatic Melanoma Trial in Boston (CDX-301, NEOVAX, Nivolumab)

Recruiting
  • Melanoma
  • Metastatic Melanoma
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 12, 2023

Glioblastoma, GBM, Glioblastoma Multiforme Trial in Los Angeles, Boston, New York (Nivolumab-Placebo, Nivolumab,

Recruiting
  • Glioblastoma
  • +3 more
  • Nivolumab-Placebo
  • +4 more
  • Los Angeles, California
  • +3 more
Jan 16, 2023

Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,

Recruiting
  • Metastatic Gastric Cancer
  • +2 more
  • Nivolumab
  • +2 more
  • New York, New York
    Bureau for Cancer Research
May 10, 2023

Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8 Trial

Not yet recruiting
  • Metastatic Nasopharyngeal Carcinoma
  • +2 more
  • Nivolumab
  • +5 more
  • (no location specified)
Aug 21, 2023

Metastatic Renal Cell Carcinoma Trial in Italy (Axitinib, Nivolumab)

Not yet recruiting
  • Metastatic Renal Cell Carcinoma
  • Brescia, Italy
  • +22 more
Apr 19, 2023

Metastatic Renal Cell Carcinoma Trial in Cleveland (Nivolumab, Ipilimumab)

Active, not recruiting
  • Metastatic Renal Cell Carcinoma
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Jan 25, 2023

Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Cancer Trial in Israel, United States (CM-24 and Nivolumab - Dose

Recruiting
  • Solid Tumor
  • +6 more
  • CM-24 and Nivolumab - Dose Escalation
  • +4 more
  • Scottsdale, Arizona
  • +10 more
Jan 17, 2023

Safety Issues, Efficacy, Self Trial in Monterrey (low dose nivolumab in combination with AVD)

Recruiting
  • Safety Issues
  • Efficacy, Self
  • low dose nivolumab in combination with AVD
  • Monterrey, Nuevo Leon, Mexico
    Hospital Universitario Dr Jose Eleuterio Gonzalez
Mar 6, 2023